Immunic Inc (NASDAQ:IMUX)

2.24
Delayed Data
As of Jan 27
 0.00 / 0.00%
Today’s Change
1.11
Today|||52-Week Range
14.50
+60.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$82.9M

Company Description

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm's products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.

Contact Information

Immunic, Inc.
1200 Avenue of the Americas
New York New York 10036
P:(332) 255-9818
Investor Relations:
4989208087709

Employees

Shareholders

Other institutional46.20%
Mutual fund holders3.62%
Individual stakeholders2.45%

Top Executives

Daniel VittPresident, Chief Executive Officer & Director
Manfred GröppelChief Operating Officer
Glenn WhaleyChief Financial Officer
Andreas MuehlerChief Medical Officer
Hella KohlhofChief Scientific Officer